Skip to main content
Erschienen in: Strahlentherapie und Onkologie 8/2021

29.04.2021 | Original Article

Pattern of relapse in pediatric localized extremity rhabdomyosarcomas correlated with locoregional therapies administered

verfasst von: Julien Welmant, Sylvie Helfre, Matthieu Carton, Stéphanie Bolle, Véronique Minard-Colin, Nadège Corradini, Stéphanie Pannier, Angélique Rome, Ludovic Mansuy, Cécile Vérité, Marie Pierre Castex, Christine Kerr, Anne Sophie Defachelles, Valérie Bernier, Dr. Daniel Orbach

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Treatment of extremity rhabdomyosarcomas (RMS) includes chemotherapy, surgery, and radiotherapy. Lymph node irradiation is recommended in the presence of regional node involvement at diagnosis. The aim of this study was to analyze the correlation between the pattern of relapse of non-metastatic extremity RMS and the initial therapies delivered.

Methods

All patients with localized extremity RMS prospectively treated in France in the MMT-95 and RMS-05 protocols were selected. Extent of disease and pattern of relapse were evaluated by clinical examination and imaging.

Results

We identified 59 patients with clinical characteristics corresponding to unfavorable prognostic factors. Twenty patients (34%) were considered to have lymph node involvement at diagnosis. Regional node biopsy was performed in 32 patients (54%) and modified the lymph node stage in 8 of the 59 patients (14%). Seventy-three percent of patients received radiotherapy. Fifty-two patients achieved first remission. Overall, 26 patients underwent complete tumor resection, 17 had R1 margins, and 5 were not operated due to early tumor progression. With a median follow-up of 82 months (range: 5–287), 18 relapses had occurred, at least locoregional in 12 cases. The 5‑year local and nodal control rates were 73% (63–86%) and 86% (77–95%), respectively. Five-year progression-free and overall survival were 57% (95%CI [45–72%]) and 70% (95%CI [58–84%]), respectively.

Conclusion

The main sites of extremity RMS relapse are locoregional. Nodal failures in non-irradiated fields are not uncommon. We recommend systematic biopsy of in-transit nodes, especially in alveolar RMS and/or RMS with regional positive nodes at diagnosis to ensure their negativity.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Steliarova-Foucher E et al (2017) International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol 18(6):719–731PubMedPubMedCentral Steliarova-Foucher E et al (2017) International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol 18(6):719–731PubMedPubMedCentral
2.
Zurück zum Zitat Oberlin O et al (2012) Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 30(20):2457–2465CrossRefPubMed Oberlin O et al (2012) Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 30(20):2457–2465CrossRefPubMed
3.
Zurück zum Zitat Oberlin O et al (2015) Prognostic factors for outcome in localized extremity rhabdomyosarcoma. Pooled analysis from four international cooperative groups. Pediatr Blood Cancer 62(12):2125–2131CrossRefPubMedPubMedCentral Oberlin O et al (2015) Prognostic factors for outcome in localized extremity rhabdomyosarcoma. Pooled analysis from four international cooperative groups. Pediatr Blood Cancer 62(12):2125–2131CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Chisholm JC et al (2011) Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 29(10):1319–1325CrossRefPubMed Chisholm JC et al (2011) Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 29(10):1319–1325CrossRefPubMed
5.
Zurück zum Zitat Carli M et al (2004) European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 22(23):4787–4794CrossRefPubMed Carli M et al (2004) European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol 22(23):4787–4794CrossRefPubMed
6.
Zurück zum Zitat Breneman JC et al (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21(1):78–84CrossRefPubMed Breneman JC et al (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21(1):78–84CrossRefPubMed
7.
Zurück zum Zitat Neville HL et al (2000) Lymphatic mapping with sentinel node biopsy in pediatric patients. J Pediatr Surg 35(6):961–964CrossRefPubMed Neville HL et al (2000) Lymphatic mapping with sentinel node biopsy in pediatric patients. J Pediatr Surg 35(6):961–964CrossRefPubMed
8.
Zurück zum Zitat Arndt CAS, Bisogno G, Koscielniak E (2018) Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev 68:94–101CrossRefPubMed Arndt CAS, Bisogno G, Koscielniak E (2018) Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev 68:94–101CrossRefPubMed
9.
Zurück zum Zitat Gallego S et al (2018) Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer 124(15):3201–3209CrossRefPubMed Gallego S et al (2018) Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). Cancer 124(15):3201–3209CrossRefPubMed
10.
Zurück zum Zitat Paulino AC, Pappo A (2009) Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk? Pediatr Blood Cancer 53(7):1332–1333CrossRefPubMed Paulino AC, Pappo A (2009) Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk? Pediatr Blood Cancer 53(7):1332–1333CrossRefPubMed
11.
Zurück zum Zitat Lobeck I et al (2017) Quality assessment of lymph node sampling in rhabdomyosarcoma: a surveillance, epidemiology, and end results (SEER) program study. J Pediatr Surg 52(4):614–617CrossRefPubMed Lobeck I et al (2017) Quality assessment of lymph node sampling in rhabdomyosarcoma: a surveillance, epidemiology, and end results (SEER) program study. J Pediatr Surg 52(4):614–617CrossRefPubMed
12.
Zurück zum Zitat Bisogno G et al (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20(11):1566–1575CrossRefPubMed Bisogno G et al (2019) Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20(11):1566–1575CrossRefPubMed
13.
Zurück zum Zitat Bisogno G et al (2005) The IVADo regimen—a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European Pediatric Soft Tissue Sarcoma Study Group. Cancer 103(8):1719–1724CrossRefPubMed Bisogno G et al (2005) The IVADo regimen—a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European Pediatric Soft Tissue Sarcoma Study Group. Cancer 103(8):1719–1724CrossRefPubMed
14.
Zurück zum Zitat Donaldson SS et al (1986) Topography of childhood tumors: pediatric coding system. Pediatr Hematol Oncol 3(3):249–258CrossRefPubMed Donaldson SS et al (1986) Topography of childhood tumors: pediatric coding system. Pediatr Hematol Oncol 3(3):249–258CrossRefPubMed
15.
Zurück zum Zitat Bisogno G et al (2018) Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 19(8):1061–1071CrossRefPubMed Bisogno G et al (2018) Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet Oncol 19(8):1061–1071CrossRefPubMed
16.
Zurück zum Zitat Maurer HM et al (1988) The intergroup rhabdomyosarcoma study. I. A final report. Cancer 61(2):209–220CrossRefPubMed Maurer HM et al (1988) The intergroup rhabdomyosarcoma study. I. A final report. Cancer 61(2):209–220CrossRefPubMed
17.
Zurück zum Zitat Gallego S et al (2021) Alveolar rhabdomyosarcoma with regional nodal involvement: results of a combined analysis from two cooperative groups. Pediatr Blood Cancer 68(3):e28832CrossRefPubMed Gallego S et al (2021) Alveolar rhabdomyosarcoma with regional nodal involvement: results of a combined analysis from two cooperative groups. Pediatr Blood Cancer 68(3):e28832CrossRefPubMed
18.
Zurück zum Zitat Elmanzalawy A et al (2020) The impact of (18)F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients. Pediatr Radiol 50(2):252–260CrossRefPubMed Elmanzalawy A et al (2020) The impact of (18)F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients. Pediatr Radiol 50(2):252–260CrossRefPubMed
19.
Zurück zum Zitat Volker T et al (2007) Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25(34):5435–5441CrossRefPubMed Volker T et al (2007) Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25(34):5435–5441CrossRefPubMed
20.
Zurück zum Zitat Ricard F et al (2011) Additional benefit of F‑18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med 36(8):672–677CrossRefPubMed Ricard F et al (2011) Additional benefit of F‑18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med 36(8):672–677CrossRefPubMed
21.
Zurück zum Zitat Wharam MD et al (2004) Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 22(10):1902–1908CrossRefPubMed Wharam MD et al (2004) Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 22(10):1902–1908CrossRefPubMed
22.
Zurück zum Zitat McMulkin HM et al (2003) Sentinel lymph node mapping and biopsy: a potentially valuable tool in the management of childhood extremity rhabdomyosarcoma. Pediatr Surg Int 19(6):453–456CrossRefPubMed McMulkin HM et al (2003) Sentinel lymph node mapping and biopsy: a potentially valuable tool in the management of childhood extremity rhabdomyosarcoma. Pediatr Surg Int 19(6):453–456CrossRefPubMed
23.
Zurück zum Zitat Turpin B et al (2019) Sentinel lymph node biopsy in head and neck rhabdomyosarcoma. Pediatr Blood Cancer 66(3):e27532CrossRefPubMed Turpin B et al (2019) Sentinel lymph node biopsy in head and neck rhabdomyosarcoma. Pediatr Blood Cancer 66(3):e27532CrossRefPubMed
24.
Zurück zum Zitat Dall’Igna P et al (2014) Sentinel node biopsy in pediatric patients: the experience in a single institution. Eur J Pediatr Surg 24(6):482–487CrossRefPubMed Dall’Igna P et al (2014) Sentinel node biopsy in pediatric patients: the experience in a single institution. Eur J Pediatr Surg 24(6):482–487CrossRefPubMed
25.
Zurück zum Zitat Lautz TB et al (2021) Benefit of delayed primary excision in rhabdomyosarcoma: a report from the Children’s Oncology Group. Cancer 127(2):275–283CrossRefPubMed Lautz TB et al (2021) Benefit of delayed primary excision in rhabdomyosarcoma: a report from the Children’s Oncology Group. Cancer 127(2):275–283CrossRefPubMed
26.
Zurück zum Zitat Orbach D et al (2017) Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies. Head Neck 39(1):24–31CrossRefPubMed Orbach D et al (2017) Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies. Head Neck 39(1):24–31CrossRefPubMed
27.
Zurück zum Zitat Reguerre Y et al (2012) Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee. Eur J Cancer 48(13):2020–2027CrossRefPubMed Reguerre Y et al (2012) Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee. Eur J Cancer 48(13):2020–2027CrossRefPubMed
28.
Zurück zum Zitat Morris CD et al (2020) Surgical management of extremity rhabdomyosarcoma: a consensus opinion from the Children’s Oncology Group, the European Pediatric Soft-Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.28608CrossRefPubMed Morris CD et al (2020) Surgical management of extremity rhabdomyosarcoma: a consensus opinion from the Children’s Oncology Group, the European Pediatric Soft-Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatr Blood Cancer. https://​doi.​org/​10.​1002/​pbc.​28608CrossRefPubMed
29.
Zurück zum Zitat La TH et al (2011) Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children’s Oncology Group. Int J Radiat Oncol Biol Phys 80(4):1151–1157CrossRefPubMed La TH et al (2011) Regional nodal involvement and patterns of spread along in-transit pathways in children with rhabdomyosarcoma of the extremity: a report from the Children’s Oncology Group. Int J Radiat Oncol Biol Phys 80(4):1151–1157CrossRefPubMed
Metadaten
Titel
Pattern of relapse in pediatric localized extremity rhabdomyosarcomas correlated with locoregional therapies administered
verfasst von
Julien Welmant
Sylvie Helfre
Matthieu Carton
Stéphanie Bolle
Véronique Minard-Colin
Nadège Corradini
Stéphanie Pannier
Angélique Rome
Ludovic Mansuy
Cécile Vérité
Marie Pierre Castex
Christine Kerr
Anne Sophie Defachelles
Valérie Bernier
Dr. Daniel Orbach
Publikationsdatum
29.04.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 8/2021
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-021-01780-7

Weitere Artikel der Ausgabe 8/2021

Strahlentherapie und Onkologie 8/2021 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.